UBE2W, or ubiquitin-conjugating enzyme E2 W, is a member of the E2 ubiquitin-conjugating enzyme family and plays a unique role in the ubiquitination process, whereby ubiquitin, a small regulatory protein, is attached to substrates. This post-translational modification can signal for protein degradation, alter protein function, or affect protein localization.The UBE2W gene encodes the UBE2W enzyme in humans. Unlike other E2 enzymes that typically attach ubiquitin to the ε-amino group of lysine residues on substrate proteins, UBE2W is known to have the distinctive capability to attach ubiquitin to the N-terminus of substrate proteins, a process known as N-terminal ubiquitination. This form of ubiquitination can mark proteins for degradation by the proteasome, a protein complex responsible for degrading unneeded or damaged proteins by proteolysis, which is a significant cellular mechanism for regulating protein levels and function.
N-terminal ubiquitination by UBE2W is particularly important because it widens the diversity of ubiquitination's impact on cellular processes. UBE2W's activity is implicated in the regulation of various cellular processes, including the DNA damage response, signal transduction pathways, and the cell cycle.Altered function or dysregulation of UBE2W has been associated with several human diseases, including cancer. The enzyme's role in modulating protein stability and function makes it a potential target for intervention, and understanding its activity is important for the development of drugs that can manipulate ubiquitination pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
Ubiquitin-activating enzyme inhibitor; could alter ubiquitination dynamics involving UBE2W. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Modulates ubiquitin ligase activity; potential indirect effects on UBE2W function. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
NEDD8-activating enzyme inhibitor; may affect cullin-RING ligase activity, influencing UBE2W. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Alters endosomal pH; could influence cellular processes related to UBE2W activity. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Proteasome inhibitor; might stabilize substrates of UBE2W, indirectly affecting its function. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Inhibits N-linked glycosylation, potentially impacting protein stability and UBE2W activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor; could modulate signaling pathways affecting UBE2W. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor; may impact pathways influencing UBE2W-mediated ubiquitination. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Kinase inhibitor; could indirectly influence UBE2W through various signaling pathways. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
MDM2 antagonist; might affect p53-related pathways, indirectly impacting UBE2W. | ||||||